Primary efficacy endpoint
The proportion of responders on Day 8 was 43.2% (19/44) in the group receiving lusutrombopag and 4.5% (1/22) in the control placebo group. Between these groups, the proportion difference was statistically significant at 38.6% (Percentage of responders in the placebo and lusutrombopag groups on Day 8 in FAS population. Responder is the patient with PLT ≥ 50 × 10The median values of PLT on Day 8 (the day after 7-day treatment) were 61.5 × 10Subgroup analysis of the percentage of responders in the placebo and lusutrombopag groups on Day 8 in FAS population. Data are presented as number of patients/ total number of subgroups and percentage of patients. Responder is the patient with PLT ≥ 50 × 10